← Product Code [QVF](/productcode/QVF) · K261379

# BD Veritor System for SARS-CoV-2 (K261379)

_BD Diagnostic Solutions / Becton, Dickinson & Company · QVF · Oct 27, 2026 · Microbiology · SESE_

**Canonical URL:** https://fda.innolitics.com/device/K261379

## Device Facts

- **Applicant:** BD Diagnostic Solutions / Becton, Dickinson & Company
- **Product Code:** [QVF](/productcode/QVF.md)
- **Decision Date:** Oct 27, 2026
- **Decision:** SESE
- **Submission Type:** Dual Track
- **Regulation:** 21 CFR 866.3982
- **Device Class:** Class 2
- **Review Panel:** Microbiology

## Indications for Use

The BD Veritor™ System for SARS-CoV-2 is a chromatographic digital immunoassay for the rapid, qualitative detection of SARS-CoV-2 nucleocapsid protein antigens directly in anterior nasal swab specimens from individuals with signs and symptoms of upper respiratory infection (i.e., symptomatic). The test is intended for use as an aid in the diagnosis of SARS-CoV-2 infections (COVID-19) in symptomatic individuals when either: tested at least twice over three days with at least 48 hours between tests; or when tested once, and negative by the BD Veritor™ System for SARS-CoV-2 and followed up with a molecular test. A negative test result is presumptive, and does not preclude SARS-CoV-2 infection; it is recommended these results be confirmed by a molecular SARS-CoV-2 assay. Positive results do not rule out co-infection with other bacteria or viruses and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Performance characteristics for SARS-CoV-2 were established between April 2024 and August 2024 when SARS-CoV-2 Omicron was the predominant SARS-CoV-2 variant in circulation. Performance characteristics may vary with newly emerging SARS-CoV-2 virus variants.

## Device Story

Lateral flow immunochromatographic assay; detects SARS-CoV-2 nucleocapsid antigens in anterior nasal swabs. Sample processed in extraction buffer; applied to test cassette. BD Veritor Plus Analyzer (opto-electronic instrument) scans test strip; measures reflectance at specific zones (test, control, background). Proprietary algorithm subtracts nonspecific signal at negative control line from test line signal; compares result to cutoff. Instrument provides objective qualitative result (Positive/Negative/Invalid) on LCD. Used in laboratory or near-patient settings by healthcare providers. Enables rapid diagnosis; aids clinical management; requires molecular confirmation for negative results.

## Clinical Evidence

Bench testing only. Specimen stability study evaluated negative and low-positive (2x LoD) samples across various temperatures (4°C, 30°C, 35°C, -20°C) and durations up to 26.4 hours. All samples yielded expected results (0/5 negative, 5/5 positive).

## Technological Characteristics

Lateral flow immunochromatography; nitrocellulose membrane; colloidal gold nanoparticle conjugates. Reflectance-based opto-electronic measurement. Powered by Li-ion battery/wall transformer. Software-controlled interpretation via BD Veritor Plus Analyzer (firmware V6.10+). Standards: ISO 14971, ISO 20417, ISO 15223-1, CLSI EP25.

## Regulatory Identification

The Sofia 2 SARS Antigen+ FIA is a lateral flow immunofluorescent sandwich assay used with the Sofia 2 instrument for the rapid, qualitative detection of SARS-CoV-2 nucleocapsid protein antigens directly in anterior nasal swab specimens from symptomatic individuals. It is intended as an aid in the diagnosis of SARS-CoV-2 infections (COVID-19) in symptomatic individuals when tested at least twice over three days with at least 48 hours between tests.

## Predicate Devices

- BD Veritor™ System for SARS-CoV-2 ([K243872](/device/K243872.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{1}

U.S. FOOD & DRUG

ADMINISTRATION

### 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION

### DECISION SUMMARY

### ASSAY AND INSTRUMENT

### I Background Information:

A 510(k) Number

K261379

B Applicant

Becton, Dickinson and Company

C Proprietary and Established Names

BD Veritor System for SARS-CoV-2

D Regulatory Information

|  Product Code | Classification | Regulation Section | Panel  |
| --- | --- | --- | --- |
|  QVF | Class II | 21 CFR 866.3982 Simple point-of-care device to directly detect SARS-CoV-2 viral targets from clinical specimens in near-patient settings | Microbiology  |

### II Submission/Device Overview:

A Purpose for Submission:

To extend the specimen stability claim of BD Veritor System for SARS-CoV-2, cleared under K243872

B Measurand:

SARS-CoV-2 nucleocapsid antigens

C Type of Test:

Lateral flow immunochromatography

Food and Drug Administration

10903 New Hampshire Avenue

Silver Spring, MD 20993-0002

www.fda.gov

{2}

### III Intended Use/Indications for Use:

#### A Intended Use(s):

See Indications for Use below.

#### B Indication(s) for Use:

The BD Veritor System for SARS-CoV-2 is a chromatographic digital immunoassay for the rapid, qualitative detection of SARS-CoV-2 nucleocapsid protein antigens directly in anterior nasal swab specimens from individuals with signs and symptoms of upper respiratory infection (i.e., symptomatic). The test is intended for use as an aid in the diagnosis of SARS-CoV-2 infections (COVID-19) in symptomatic individuals when either: tested at least twice over three days with at least 48 hours between tests; or when tested once, and negative by the BD Veritor System for SARS-CoV-2 and followed up with a molecular test.

A negative test result is presumptive and does not preclude SARS-CoV-2 infection; it is recommended these results be confirmed by a molecular SARS-CoV-2 assay.

Positive results do not rule out co-infection with other bacteria or viruses and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions.

Performance characteristics for SARS-CoV-2 were established between April 2024 and August 2024 when SARS-CoV-2 Omicron was the predominant SARS-CoV-2 variant in circulation. Performance characteristics may vary with newly emerging SARS-CoV-2 virus variants.

#### C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only
IVD - For In Vitro Diagnostic Use Only

#### D Special Instrument Requirements:

The BD Veritor System for SARS-CoV-2 test is intended for use with the BD Veritor Plus Analyzer (hardware V2.00/firmware V6.10 or later).

### IV Device/System Characteristics:

#### A Device Description:

The BD Veritor System for SARS-CoV-2 is a rapid (approximately 15 minutes) qualitative chromatographic digital immunoassay for the direct detection of nucleocapsid protein antigens from SARS-CoV-2 in direct anterior nasal swab specimens collected from patients with signs and symptoms of COVID-19 by a healthcare provider. The test is intended for interpretation in laboratory and near patient testing environments only with the BD Veritor Plus Analyzer Instrument. The test is not intended to be interpreted visually.

The test package is composed of:

- 30 Test cassettes

K261379 - Page 2 of 10

{3}

• 30 Extraction reagent tubes
• 30 Specimen sampling swabs
- 1 SARS-CoV-2 (+) control swab (individually wrapped, single use control swab containing non-infectious, recombinant viral protein antigen with less than 0.1% sodium azide)
- 1 SARS-CoV-2 (-) control swab (individually wrapped, single use control swab containing buffer with less than 0.1% sodium azide)
• 1 Tube tray
• 1 Instructions for Use
• 1 Quick Reference Guide

### B Principle of Operation:

The test device is composed of a plastic housing, known as a cassette, that contains a test strip with the following parts: sample pad, conjugate pad, nitrocellulose membrane, and absorption pad. The patient sample is placed in the tube containing extraction buffer, where the virus particles in the sample are disrupted, exposing internal viral nucleoproteins. After disruption, the sample is dispensed into the sample well of the cassette.

When specimens are processed and added to the test device, SARS-CoV-2 antigens present in the specimen bind to biotinylated antibodies and antibodies conjugated to detector particles, colloidal gold nanoparticles, in the test strip. The biotinylated antibody-antigen-conjugate complexes migrate across the test strip to the reaction area and are captured by a line of streptavidin bound on the membrane.

![img-0.jpeg](img-0.jpeg)

Figure 1: Test device

The assay is only intended for use with an opto-electronic interpretation instrument, the BD Veritor Plus Analyzer Instrument and is not interpreted visually. The analyzer measures the amount of light reflected from various zones along the assay strip. The measurement of the assay background zone is an important factor during the test interpretation as the reflectance value is compared to that of the control and test zones. The instrument analyzes the reflectance data to provide the proper test interpretation.

The BD Veritor test devices are designed with four spatially distinct reaction zones (Figure 2).

K261379 - Page 3 of 10

{4}

![img-1.jpeg](img-1.jpeg)

Figure 2: Reaction zones on the test device: positive control position (C), test line position for SARS-CoV-2 (T), negative control position, and background zone.

A positive result is determined by the analyzer when antigen-conjugate is deposited at the Test "T" position and a control conjugate is deposited at the Control "C" position on the assay device. Two of the four distinct zones on the test device, negative control and background, are not labeled. The active negative control feature in each test identifies and compensates for specimen-related, nonspecific signal generation. The remaining zone is used to measure the assay background. The analyzer automatically scans the test strip, collects and analyzes the data, and then calculates and reports the result as either positive, negative, or invalid. The instrument analyzes and corrects for non-specific binding and detects positives not recognized by the unaided eye to provide an objective result. The analyzer uses a proprietary algorithm which subtracts nonspecific signal at the negative control line from the signal present at the test line. If the resultant test line signal is below the cutoff, the specimen is scored as negative. Use of the active negative control feature allows the BD Veritor System to correctly interpret test results that cannot be scored visually because the human eye is unable to accurately perform the subtraction of the nonspecific signal.

![img-2.jpeg](img-2.jpeg)

Figure 3: Test Device inserted into the BD Veritor Plus Analyzer

The analyzer is a portable, electronic instrument that uses a reflectance-based measurement method to evaluate line signal intensities on the assay test device. It applies assay-specific firmware algorithms to determine the presence or absence of target analyte(s). The analyzer is powered by a rechargeable Li-ion battery and compact wall transformer, is intended for tabletop or benchtop use, and follows the original BD Veritor instrument model of a calibration-free limited lifetime based on the number of tests performed, the number of days from first use, and/or the maximum shelf life from the date of manufacture. Procedures to evaluate test devices depend on the BD Veritor Plus Analyzer workflow configuration chosen. In Analyze Now mode, the instrument evaluates assay devices after manual timing of their development. In Walk Away mode, devices are inserted immediately after application of the specimen, and timing of assay development and analysis is automated. In either case, assay results are provided to the operator on the liquid crystal display (LCD) display screen. Additional result documentation capabilities

K261379 - Page 4 of 10

{5}

are possible with the use of a BD Veritor bar code scanning module, which can capture, display and/or integrate barcoded specimen, operator, or kit information in the test record.

# C Instrument Description Information:

1. Instrument Name:

BD Veritor Plus Analyzer (hardware V2.00/firmware V6.10 or later)

2. Specimen Identification:

Specimen IDs may be manually entered or scanned via the barcode scanner.

3. Specimen Sampling and Handling:

Anterior nasal swab samples are manually transferred to test kit reagent tubes for elution and drop-wise addition to the test cassette.

4. Calibration:

Not applicable

5. Quality Control:

The test includes a positive control to ensure adequate migration of the reagents through the test membrane to the desired test line locations for the reader. The test also contains a negative control to test for non-specific binding and a background region to measure assay background when calculating test line signal strength. 1 positive and 1 negative control swab are provided per kit. Additional external controls may also be purchased separately (BD Veritor SARS-CoV-2 Control Swabs). It is the manufacturer's recommendation that external quality controls be run after every new kit lot, when a new operator performs the test, a new shipment of test kits is received, and as required by local, state, and federal regulations. An analyzer verification cartridge is supplied to verify the BD Veritor Plus Analyzer is functioning within specifications.

# V Substantial Equivalence Information:

A Predicate Device Name(s):

BD Veritor System for SARS-CoV-2

B Predicate 510(k) Number(s):

K243872

K261379 - Page 5 of 10

{6}

C Comparison with Predicate(s):

|  Device & Predicate Device(s): | CANDIDATE DEVICE K261379 | PREDICATE DEVICE K243872  |
| --- | --- | --- |
|  Device Trade Name | BD Veritor System for SARS-CoV-2 | BD Veritor System for SARS-CoV-2  |
|  **General Device Characteristic Similarities**  |   |   |
|  Intended Use/Indications For Use | The BD Veritor System for SARS-CoV-2 is a chromatographic digital immunoassay for the rapid, qualitative detection of SARS-CoV-2 nucleocapsid protein antigens directly in anterior nasal swab specimens from individuals with signs and symptoms of upper respiratory infection (i.e., symptomatic). The test is intended for use as an aid in the diagnosis of SARS-CoV-2 infections (COVID-19) in symptomatic individuals when either: tested at least twice over three days with at least 48 hours between tests; or when tested once, and negative by the BD Veritor System for SARS-CoV-2 and followed up with a molecular test. A negative test result is presumptive and does not preclude SARS-CoV-2 infection; it is recommended these results be confirmed by a molecular SARS-CoV-2 assay. Positive results do not rule out co-infection with other bacteria or viruses and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Performance characteristics for SARS-CoV-2 were established between April 2024 and August 2024 when SARS-CoV-2 Omicron was the predominant SARS-CoV-2 variant in circulation. Performance characteristics may vary with newly emerging SARS-CoV-2 virus variants. | Same  |
|  Specimen type | Direct anterior nasal swab | Same  |

K261379 - Page 6 of 10

{7}

|  Device & Predicate Device(s): | CANDIDATE DEVICE K261379 | PREDICATE DEVICE K243872  |
| --- | --- | --- |
|  Analyte | SARS-CoV-2 nucleocapsid protein | Same  |
|  Test Type | Lateral flow immunochromatographic | Same  |
|  Test Result Type | Qualitative | Same  |
|  Test Time | 15-20 minutes | Same  |
|  Analyzer | BD Veritor Plus Analyzer | Same  |
|  Results Interpretation | Instrument read - BD Veritor Plus Analyzer scans the test strip and analyzes the reflectance data to provide the proper test interpretation. The Analyzer displays the test results (Positive, Negative, or Invalid) on the screen. | Same  |

# VI Standards/Guidance Documents Referenced:

|  Document number | Title | Publishing Organization  |
| --- | --- | --- |
|  14971 3^{rd} edition 2019-12 | Medical devices- Application of risk management to medical devices | ISO  |
|  20417 1^{st} edition 2021-04, corrected version 2021-12 | Medical devices - Information to be supplied by the manufacturer | ISO  |
|  15223-1 4^{th} edition 2021-07 | Medical devices- Symbols to be used with information to be supplied by the manufacturer- Part 1 | ISO  |
|  EP25 2^{nd} edition | Evaluation of Stability of In Vitro Medical Laboratory Test Reagents | CLSI  |

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

See Decision Summary for K243872.

2. Linearity:

This study is not applicable as this test device is a qualitative assay.

3. Analytical Specificity/Interference:

See Decision Summary for K243872.

K261379 - Page 7 of 10

{8}

#### 4. Assay Reportable Range:

This section is not applicable as this test device is a qualitative assay.

#### 5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

See Decision Summary for K243872 for internal and external controls, reagent stability/shelf-life, and open-kit stability studies.

#### Specimen Stability Study:

Two test samples were prepared for the specimen stability study: a negative sample (i.e., negative clinical matrix (NCM) with no analyte), and a low positive sample (containing diluted SARS-CoV-2 at 2x LoD in NCM). Swabs were spiked with 50  \( \mu \) L of each sample, placed inside sterile containers, and transferred to a temperature chamber set to the specified temperatures for a specified duration of time summarized in the table below. The samples were extracted at room temperature where the extracted specimen (i.e. extraction tubes containing the extracted samples) were transferred to a temperature chamber set to the same specified temperature and stored in the chamber for the specified duration. Subsequently, the extracted sample swabs were tested using 5 replicates. Acceptable performance was observed at all time points tested as shown below.

Table 1: Specimen Stability Study Results

|  Condition | Time (h) | NCM Positive/Total | SARS-CoV-2 Positive/Total  |
| --- | --- | --- | --- |
|  Room temperature (control) | 0 | 0/5 | 5/5  |
|  30°C | 0.4 | 0/5 | 5/5  |
|   |  4 | 0/5 | 5/5  |
|   |  24 | 0/5 | 5/5  |
|   |  26.4 | 0/5 | 5/5  |
|  35°C | 4 | 0/5 | 5/5  |
|   |  24 | 0/5 | 5/5  |
|   |  26.4 | 0/5 | 5/5  |
|  4°C | 4 | 0/5 | 5/5  |
|   |  24 | 0/5 | 5/5  |
|   |  26.4 | 0/5 | 5/5  |

Formatted: Keep with next

K261379 - Page 8 of 10

{9}

|  Condition | Time (h) | NCM Positive/Total | SARS-CoV-2 Positive/Total  |
| --- | --- | --- | --- |
|  -20°C | 4 | 0/5 | 5/5  |
|   |  24 | 0/5 | 5/5  |
|   |  26.4 | 0/5 | 5/5  |

Given that the device is intended for use in CLIA-waived environment, the freshly collected specimen should be processed as soon as possible after collection.

6. Detection Limit:

See Decision Summary for K243872.

7. High-Dose Hook Effect Study:

See Decision Summary for K243872.

8. Inclusivity (Analytical Reactivity):

See Decision Summary for K243872.

9. Assay Cut-Off:

See Decision Summary for K243872.

10. Accuracy (Instrument):

See Decision Summary for K243872.

11. Carry-Over:

See Decision Summary for K243872.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

See Decision Summary for K243872.

2. Matrix Comparison:

See Decision Summary for K243872.

K261379 - Page 9 of 10

{10}

# **C Clinical Studies:**

1. Clinical Sensitivity:

See Decision Summary for K243872.

2. Clinical Specificity:

See Decision Summary for K243872.

3. Serial Testing:

See Decision Summary for K243872.

4. Clinical Cut-Off

This section is not applicable; there is no clinical cutoff related to the presence of SARS-CoV-2 in patient samples.

# **D Expected Values/Reference Range:**

A patient sample is expected to be negative for SARS-CoV-2.

# **VIII Proposed Labeling:**

The proposed labeling supports the finding of substantial equivalence for this device.

# **IX Conclusion:**

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

K261379 - Page 10 of 10

---

**Source:** [https://fda.innolitics.com/device/K261379](https://fda.innolitics.com/device/K261379)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com
